The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
about
Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanismsMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases?Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's diseaseGenetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disordersExercise is not beneficial and may accelerate symptom onset in a mouse model of Huntington's diseaseAltered dopamine and serotonin metabolism in motorically asymptomatic R6/2 miceBDNF signaling and survival of striatal neurons.Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's diseaseBDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 miceAllele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 miceNew insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseases.Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease.Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia.Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?ApoE is required for maintenance of the dentate gyrus neural progenitor poolTricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system.Characterising Upper Limb Movements in Huntington's Disease and the Impact of Restricted Visual Cues.Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse modelThe group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceThe antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's diseaseMethylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease modelsExtensive changes in DNA methylation are associated with expression of mutant huntingtin.Voluntary exercise or amphetamine treatment, but not the combination, increases hippocampal brain-derived neurotrophic factor and synapsin I following cortical contusion injury in rats.Targeting sirtuin-1 in Huntington's disease: rationale and current status.A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.Escitalopram and enhancement of cognitive recovery following stroke.Patterns of serotonergic antidepressant usage in prodromal Huntington diseaseA small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia.Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.
P2860
Q21131050-C8BD48FC-1A99-43FE-A1CD-9B00CE3113FDQ27005950-8AE0321F-EB85-4200-9B5F-C1BA3518815DQ27012489-97B9F48F-0362-41B9-AF4F-33DEEFCED894Q27314860-27B3BAF5-44A1-4C96-9207-AE0D273A04F8Q28594357-74DA8852-48E1-4542-B2E7-EF55BC8E66B8Q30401432-F5A6AF1D-9045-47FA-BD0E-5E54C3CA8B69Q33664105-C857F5A0-B073-44B9-8A58-C21C76339678Q33672712-57DB5505-B422-4389-9D16-B9C4551985ABQ33769984-00FF7A28-2DF5-4CCA-9147-A01B33B28967Q33869789-FE1737F8-8D4E-4B84-BEEE-1B969E0B3821Q34102098-9ABD7DBE-6460-4507-9924-7629A492CC9BQ34272602-F8AB3E24-0772-4EA6-A774-53709F0DF7BCQ34330172-2C633A7B-00D0-479A-807C-09987AE6F784Q34338809-D981F4C0-D09C-4FC7-898D-0C31B8F5E324Q34348297-1BD21A9A-257E-4C1F-9FC6-E2214F35E311Q34459323-0E4499A9-0F9D-4695-B226-06018D23C233Q34567939-8BBB7CDA-B511-4F6B-A7AC-A639236C6A05Q34714277-84306F7E-96D0-48E7-9431-4B3DA4CD4C1FQ35054548-81936F4C-D4AE-4228-81F4-428DFAB31676Q35158376-B9DA14E3-D195-4D4A-A0D3-6BB91A287908Q35224557-AB5B38BB-400D-4233-907C-00FF90BB840CQ35243291-8523D771-768E-41B6-8C85-23756A9130C6Q35738853-ADD538BD-067A-4C3E-88AE-D0658075B9FBQ35874667-40129B31-8D2A-4885-95F2-BEB0CA6134B2Q36024880-4395859D-8833-4069-A192-4BE8693440C6Q36025447-2A1F13ED-71AF-47F9-AB27-F5C3E513918CQ36037085-5B9C8151-4DDE-410C-BDDB-8599ED32488EQ36086462-475D8A24-A70C-4144-A5C7-DE6C6AF62E47Q36088666-A6936C0A-9138-4CA1-B594-15A34CFD3C39Q36538885-74F2291E-060F-447B-8048-0607E536ECB7Q36598186-2A872AC2-1C5F-4B14-9487-EA370B1D1BC9Q36739453-7D34F67E-0760-482F-9A8E-382507924B42Q36863901-8BEF4985-7582-452F-A894-2EA1B1416C1FQ36993596-CC2EE486-0CD2-4364-A58D-4E1F5E3262D8Q37032754-A29B6CC6-23FB-451B-8021-84C704BDCABCQ37148863-D1DE512F-59E0-4825-893E-8C718ECE04F6Q37345118-A1BB9C84-E729-4A8A-8A4E-28D707AA65D2Q37607467-CBB02EAA-DD6C-4215-8797-C1988690E09BQ37641665-CA362AD7-6207-423D-ACAD-34571EF11E5EQ37928965-168FF1C3-DBA9-4DBE-A8BB-1FCDADCE85A6
P2860
The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The antidepressant sertraline ...... tington's disease mouse model.
@en
The antidepressant sertraline ...... tington's disease mouse model.
@nl
type
label
The antidepressant sertraline ...... tington's disease mouse model.
@en
The antidepressant sertraline ...... tington's disease mouse model.
@nl
prefLabel
The antidepressant sertraline ...... tington's disease mouse model.
@en
The antidepressant sertraline ...... tington's disease mouse model.
@nl
P2093
P2860
P1476
The antidepressant sertraline ...... tington's disease mouse model.
@en
P2093
P2860
P304
P356
10.1016/J.EXPNEUROL.2007.10.015
P407
P577
2007-11-09T00:00:00Z